Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Viola

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
The Journal of Clinical Endocrinology and Metabolism|June 1, 2021
Tall cell percentage alone in PTC without aggressive features should not guide patients' clinical managementAnello Marcello Poma, David Viola, Elisabetta Macerola, et al.
European Thyroid Journal|September 20, 2021
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid CancerLaura Valerio, Carlotta Giani, Laura Agate, et al.
Plant Biotechnology Journal|November 21, 2007
FLP recombinase-mediated site-specific recombination in riceQian Hu, Halina Kononowicz-Hodges, Kimberly Nelson-Vasilchik, et al.
The Journal of Clinical Endocrinology and Metabolism|May 27, 2020
Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with RadioiodineAntonio Matrone, Alessio Faranda, Francesco Latrofa, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|September 27, 2019
DELAYED 131-I FIRST TREATMENT AFTER SURGERY HAS NO IMPACT ON THE MEDIAN TERM OUTCOME OF PATIENTS WITH INTERMEDIATE RISK DIFFERENTIATED THYROID CANCERAntonio Matrone, Carla Gambale, Liborio Torregrossa, et al.
Endocrine-Related Cancer|December 6, 2019
Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable responseLaura Valerio, Valeria Bottici, Antonio Matrone, et al.
The Journal of Clinical Endocrinology and Metabolism|April 30, 2013
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-upEleonora Molinaro, Carlotta Giani, Laura Agate, et al.
Cancers|April 13, 2023
Outcomes of the Tall-Cell Variant of Papillary Thyroid Carcinoma in Patients with Different Ages: A 17-Year Mono-Institutional ExperienceAgnese Proietti, Francesca Signorini, Riccardo Giannini, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|September 16, 2017
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real lifeAntonio Matrone, Laura Valerio, Letizia Pieruzzi, et al.
International Journal of Molecular Sciences|April 3, 2021
Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular IdentitiesLoredana Lorusso, Virginia Cappagli, Laura Valerio, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
The Journal of Clinical Endocrinology and Metabolism|June 1, 2021
Tall cell percentage alone in PTC without aggressive features should not guide patients' clinical managementAnello Marcello Poma, David Viola, Elisabetta Macerola, et al.
European Thyroid Journal|September 20, 2021
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid CancerLaura Valerio, Carlotta Giani, Laura Agate, et al.
Plant Biotechnology Journal|November 21, 2007
FLP recombinase-mediated site-specific recombination in riceQian Hu, Halina Kononowicz-Hodges, Kimberly Nelson-Vasilchik, et al.
The Journal of Clinical Endocrinology and Metabolism|May 27, 2020
Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with RadioiodineAntonio Matrone, Alessio Faranda, Francesco Latrofa, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|September 27, 2019
DELAYED 131-I FIRST TREATMENT AFTER SURGERY HAS NO IMPACT ON THE MEDIAN TERM OUTCOME OF PATIENTS WITH INTERMEDIATE RISK DIFFERENTIATED THYROID CANCERAntonio Matrone, Carla Gambale, Liborio Torregrossa, et al.
Endocrine-Related Cancer|December 6, 2019
Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable responseLaura Valerio, Valeria Bottici, Antonio Matrone, et al.
The Journal of Clinical Endocrinology and Metabolism|April 30, 2013
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-upEleonora Molinaro, Carlotta Giani, Laura Agate, et al.
Cancers|April 13, 2023
Outcomes of the Tall-Cell Variant of Papillary Thyroid Carcinoma in Patients with Different Ages: A 17-Year Mono-Institutional ExperienceAgnese Proietti, Francesca Signorini, Riccardo Giannini, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|September 16, 2017
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real lifeAntonio Matrone, Laura Valerio, Letizia Pieruzzi, et al.
International Journal of Molecular Sciences|April 3, 2021
Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular IdentitiesLoredana Lorusso, Virginia Cappagli, Laura Valerio, et al.
Pageof 6